4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 13, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse...
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
August 05, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP...
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
June 24, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH)Complement factor...
4DMT to Participate in Upcoming Investor Conference
May 07, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
November 09, 2023 16:19 ET
|
4D Molecular Therapeutics, Inc.
Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled...
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
August 09, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD)Completed target enrollment of 50 patients in...
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
June 07, 2023 16:10 ET
|
4D Molecular Therapeutics, Inc.
Reported data from cohort 1 (n=3, 1E15 vg dose) of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up Quality of life outcomes measured by Cystic...
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
May 08, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
March 15, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for...
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
January 09, 2023 09:00 ET
|
4D Molecular Therapeutics, Inc.
Expands Large Market Ophthalmology Portfolio Following Positive Clinical Data in wet Age-Related Macular Degeneration to Include Diabetic Macular Edema Clinical Program and Geographic Atrophy...